[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363695-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363695-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pd-1-inhibits-cd4-trm-mediated-cdc1-mobilization-via-suppressing-jaml-in-human-nsclc-research-article","PD-1 Inhibits CD4+ TRM-Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC - Research article","","Tissue-resident memory CD4+ T cells (CD4+ TRMs) are crucial for immune responses in inflammation and infection, yet their phenotype and roles in the tumor microenvironment remain unclear. This study delineates CD4+ TRMs in non-small cell lung cancer using CD103 and CD69 and shows they drive helper antitumor effects by secreting XCL1 to recruit cDC1 and promote antigen presentation. JAML is identified as essential for CD4+ TRM-mediated cDC1 mobilization, while PD-1 signaling suppresses JAML and XCL1 in tumor settings. PD-1 blockade and a JAML agonist enhance anti-PD-1 efficacy in tumor-bearing mice. Clinically, XCL1-secreting CD4+ TRMs associate with favorable outcomes and improved responses to anti-PD-1 immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pd-1-inhibits-cd4-trm-mediated-cdc1-mobilization-via-suppressing-jaml-in-human-nsclc-research-article/363695/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pd-1-inhibits-cd4-trm-mediated-cdc1-mobilization-via-suppressing-jaml-in-human-nsclc-research-article/363695.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How are CD4+ TRMs defined in non-small cell lung cancer in this study?","Question",{"text":63,"@type":64},"CD4+ TRMs are delineated using CD103 and CD69 as defining markers in NSCLC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do CD4+ TRMs play in recruiting cDC1 and promoting antitumor immunity?",{"text":68,"@type":64},"Tumor-infiltrating CD4+ TRMs secrete XCL1 to recruit conventional type 1 dendritic cells (cDC1s), facilitating antigen presentation and priming cytotoxic T lymphocyte responses.",{"name":70,"@type":61,"acceptedAnswer":71},"How does PD-1 signaling affect JAML and the CD4+ TRM-mediated cDC1 mobilization process?",{"text":72,"@type":64},"PD-1 signaling suppresses JAML expression in the NSCLC tumor microenvironment, reducing CD4+ TRM-driven cDC1 mobilization; this effect is reversible by PD-1 blockade.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363695,1790280325,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Advanced Science  \nSPECIAL ISSUE Advances in Cancer Immunotherapy  \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nPD-1 Inhibits CD4+ TRM-Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC  \nZheyu Shao1, 2  Qinyuan Liu1, 2  Zhongwei Xin3  Zhiyao Zhou1, 2  Mingjie Lin1, 2 Yongyuan Chen1, 2  Wenxuan Wu2, 5  Shuyang Zhang6  Xiaoke Chen1, 2  Xia Xu7 Yuhao Lu1, 2  Dang Wu2, 4  Pin Wu1, 2   \nDi Chen2, 4 Jinfan Li7  \nZhixing Hao2, 5 Wei Lin8   \n1 Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China  2 Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China  3 Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China  4 Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China  5 Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China  6 Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China  7 Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China  8 Department of Thoracic  \nSurgery, The Second Affiliated Hospital Linping Campus, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China Correspondence: Dang Wu ([wudang@zju.edu.cn](wudang@zju.edu.cn))  Pin Wu (pinwu@zju.edu.cn)  \nReceived: 28 April 2025  Revised: 28 November 2025  Accepted: 17 December 2025  \nKeywords: conventional type 1 dendritic cells (cDC1) | junction adhesion molecule-like protein (JAML) | non-small cell lung cancer (NSCLC) | programmed cell death protein 1 (PD-1) | tissue-resident memory CD4+ T cells (CD4+ TRMs) | X-C motif chemokine ligand 1 (XCL1)  \nABSTRACT  \nTissue-resident memory CD4+ T cells (CD4+ TRMs) are pivotal in immune responses during inflammation and infection, yet their phenotype and function within the tumor microenvironment (TME) remain elusive. Here, we delineated CD4+ TRMs in non-small cell lung cancer (NSCLC) using CD103 and CD69 as defining markers and demonstrated that their transcriptional and phenotypic profiles closely resembled those observed in murine models. Tumor-infiltrating CD4+ TRMs exert helper antitumor effects by secreting the chemokine XCL1 to recruit conventional type 1 dendritic cells (cDC1s), facilitating antigen presentation and priming cytotoxic T lymphocyte responses. Mechanistically, we identified the costimulatory molecule JAML as essential for CD4+TRM-mediated cDC1 mobilization. Compared with their counterpartsin normal lung tissue, tumor-infiltrating CD4+TRMs exhibited elevated expression of immune checkpoint molecules, indicating a dysfunctional state, accompanied by significantly reduced XCL1 expression. PD-1 signaling within the NSCLC TME suppressed JAML expression—an effect reversible by PD-1 blockade—while the administration of a JAML agonist further enhanced the antitumor efficacy of PD-1 inhibitors in tumorbearing mice. Clinically, the presence of XCL1-secreting CD4+ TRMs positively correlated with favorable clinical outcomes and enhanced responses to anti-PD-1 immunotherapy in NSCLC patients. Our findings reveal a critical role for JAML in facilitating CD4+ TRM-mediated cDC1 mobilization within the NSCLC TME and highlight the translational potential of targeting CD4+ TRMs to enhance the efficacy of immune checkpoint blockade therapies.  \n\n| Zheyu Shao, Qinyuan Liu, Zhongwei Xin, and Zhiyao Zhou contributed equally to this work.\u003Cbr>|\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License,","cbCaiq5ASiXGwwoR","https://ap.wps.com/l/cbCaiq5ASiXGwwoR","pdf",7935399,26,"English","# Introduction\n## Background and rationale\n## CD4+ TRMs in cancer immunity","[{\"question\":\"How are CD4+ TRMs defined in non-small cell lung cancer in this study?\",\"answer\":\"CD4+ TRMs are delineated using CD103 and CD69 as defining markers in NSCLC.\"},{\"question\":\"What role do CD4+ TRMs play in recruiting cDC1 and promoting antitumor immunity?\",\"answer\":\"Tumor-infiltrating CD4+ TRMs secrete XCL1 to recruit conventional type 1 dendritic cells (cDC1s), facilitating antigen presentation and priming cytotoxic T lymphocyte responses.\"},{\"question\":\"How does PD-1 signaling affect JAML and the CD4+ TRM-mediated cDC1 mobilization process?\",\"answer\":\"PD-1 signaling suppresses JAML expression in the NSCLC tumor microenvironment, reducing CD4+ TRM-driven cDC1 mobilization; this effect is reversible by PD-1 blockade.\"}]","PD-1 Inhibits CD4+ TRM-Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC - Research article | PDF",1790152716,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/816242a0aaae8e952f79dd2b91a33385.webp",983,1283,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/850a5a191227944eab1daff452a084a2.webp",982,1281,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5665506b055acdacc77b5ccc94bc508c.webp",981,1280,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f43a817ca4905429839f065eb4c26c28.webp",980,1279]